Hence, the proposal that the CB1 antagonist, rimonabant, could be used to treat obesity in humans was an important step, although depressive and anxiogenic side effects rapidly ended this therapeutic approach [43,44]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.